Roberto Fernández-Torrón

Roberto Fernández-Torrón

Auto-generated profile, based on publicly available information

Roberto Fernández-Torrón

Neuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Progress in Neurobiology
Verified
Journal Article
Closed access
MZMónica Zufiría
Mónica Zufiría
FGFrancisco Gil-Bea
Francisco Gil-Bea
RFRoberto Fernández-Torrón
Roberto Fernández-Torrón
JPJuan José Poza
Juan José Poza
JMJose Luis Muñoz-Blanco
Jose Luis Muñoz-Blanco
AMAdolfo López de Munain
Adolfo López de Munain

17 March 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
ECElena Cortés-Vicente
Elena Cortés-Vicente
RÁRodrigo Álvarez-Velasco
Rodrigo Álvarez-Velasco
SSSonia Segovia
Sonia Segovia
CPCarmen Paradas
Carmen Paradas
CCCarlos Casasnovas
Carlos Casasnovas
IIIsabel Illa
Isabel Illa
Objective To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). Methods This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular Diseases (NMD-ES). All patients were >18 years of age at onset of MG and onset occurred between 2000 and 2016 in all cases. Patients were classified into 3 age subgroups: early-onset MG (age at onset <50 years), late-onset MG (onset ≥50 and <65 years), and very-late-onset MG (onset ≥65 years). Demographic, immunologic, clinical, and therapeutic data were reviewed. Results A total of 939 patients from 15 hospitals were included: 288 (30.7%) had early-onset MG, 227 (24.2%) late-onset MG, and 424 (45.2%) very-late-onset MG. The mean follow-up was 9.1 years (SD 4.3). Patients with late onset and very late onset were more frequently men (p < 0.0001). Compared to the early-onset and late-onset groups, in the very-late-onset group, the presence of anti–acetylcholine receptor (anti-AChR) antibodies (p < 0.0001) was higher and fewer patients had thymoma (p < 0.0001). Late-onset MG and very-late-onset MG groups more frequently had ocular MG, both at onset (<0.0001) and at maximal worsening (p = 0.001). Although the very-late-onset group presented more life-threatening events (Myasthenia Gravis Foundation of America IVB and V) at onset (p = 0.002), they required fewer drugs (p < 0.0001) and were less frequently drug-refractory (p < 0.0001). Conclusions Patients with MG are primarily ≥65 years of age with anti-AChR antibodies and no thymoma. Although patients with very-late-onset MG may present life-threatening events at onset, they achieve a good outcome with fewer immunosuppressants when diagnosed and treated properly.

7 May 2018 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
JDJordi Diaz-Manera
Jordi Diaz-Manera
RFRoberto Fernandez-Torron
Roberto Fernandez-Torron
JLJaume Llauger
Jaume Llauger
MJMeredith K James
Meredith K James
AMAnna Mayhew
Anna Mayhew
VSVolker Straub
Volker Straub
Background and objective: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests.Methods: We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed.Results: In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment.Conclusions: The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials.Clinical trial registration: NCT01676077.

9 July 2015 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
AMAlba Judith Mateos-Aierdi
Alba Judith Mateos-Aierdi
MGMaria Goicoechea
Maria Goicoechea
AAAna Aiastui
Ana Aiastui
RFRoberto Fernández-Torrón
Roberto Fernández-Torrón
MGMikel García-Puga
Mikel García-Puga
AMAdolfo López de Munain
Adolfo López de Munain
Myotonic dystrophy type I (DM1 or Steinert’s disease) and type II (DM2) are multisystem disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the most prominent neuromuscular features of these diseases, and other clinical manifestations such as cardiomyopathy, insulin-resistance and cataracts are also common. From a clinical perspective, most DM symptoms are interpreted as a result of an accelerated aging (cataracts, muscular weakness and atrophy, cognitive decline, metabolic dysfunction, etc.), including an increased risk of developing tumors. From this point of view, DM1 could be described as a progeroid syndrome since a notable age-dependent dysfunction of all systems occurs. The underlying molecular disorder in DM1 consists of the existence of a pathological (CTG)n triplet expansion in the 3’ untranslated region of the DMPK gene, whereas (CCTG)n repeats in the first intron of the CNBP/ZNF9 gene cause DM2. The expansions are transcribed into (CUG)n and (CCUG)n-containing RNA, respectively, which form secondary structures and sequester RNA-binding proteins, such as the splicing factor muscleblind-like protein (MBNL), forming nuclear aggregates known as foci. Other splicing factors, such as CUGBP, are also disrupted, leading to a spliceopathy of a large number of downstream genes linked to the clinical features of these diseases. Skeletal muscle regeneration relies on muscle progenitor cells, known as satellite cells, which are activated after muscle damage, and which proliferate and differentiate to muscle cells, thus regenerating the damaged tissue. Satellite cell dysfunction seems to be a common feature of both age-dependent muscle degeneration (sarcopenia) and muscle wasting in DM and other muscle degenerative diseases. This review aims to describe the cellular, molecular and macrostructural processes involved in the muscular degeneration seen in DM patients, highlighting the similarities found with muscle aging.

30 August 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
AGAlberto García‐Redondo
Alberto García‐Redondo
OIOriol Dols Icardo
Oriol Dols Icardo
RRRicard Rojas‐García
Ricard Rojas‐García
JEJesús Esteban‐Pérez
Jesús Esteban‐Pérez
PBPilar Cordero‐Vázquez Bs
Pilar Cordero‐Vázquez Bs
ALAlberto Lleó
Alberto Lleó

1 November 2019 in Neuromuscular Disorders
Verified
Journal Article
Closed access
JCJodi Warman Chardon
Jodi Warman Chardon
JDJordi Díaz-Manera
Jordi Díaz-Manera
Giorgio TascaGiorgio Tasca
Giorgio Tasca
CBCarsten G. Bönnemann
Carsten G. Bönnemann
DGDavid Gómez-Andrés
David Gómez-Andrés
RCRobert Yves Carlier
Robert Yves Carlier